Exelixis earns new Buy at Goldman Sachs (EXEL:NASDAQ)
Exelixis(US:EXEL) Seeking Alphaยท2025-09-17 17:54Group 1 - Goldman Sachs initiated coverage of Exelixis (NASDAQ:EXEL) with a Buy recommendation [2] - The target price set by Goldman Sachs for Exelixis is $47 [2] - The recommendation is based on the potential of zanzalintinib to mitigate the upcoming patent cliff for Cabometyx, Exelixis's kidney cancer drug [2]